Primavera Capital Acquisition Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PV research report →
Price Chart
About the company
Primavera Capital Acquisition Corporation is not presently conducting significant business activities. Its stated objective is to pursue a business combination, which may take the form of a merger, share exchange, asset acquisition, share purchase, reorganization, or another comparable transaction, with one or more consumer companies in China. This entity was founded in 2020 and has its principal office in Central, Hong Kong.
- IPO
- 2021
- HQ
- Central, HK
Get TickerSpark's AI analysis on PV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- 11.79
- PEG
- 0.08
- P/S
- 0.00
- P/B
- -14423.48
- EV/EBITDA
- -0.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -122554.52%
- ROIC
- -837.87%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,456,000
- Net Income
- $45.21M+0.0%
- EPS
- $0.84+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $10.51
- 52W Low
- $8.96
- 50D MA
- $9.98
- 200D MA
- $9.89
- Beta
- 0.00
- RSI (14)
- 47
- Avg Volume
- 142.45K
No earnings-call transcripts are available for PV yet.
Buy/sell ratio 0.45. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 14, 22 | Primavera Capital Acquisition LLC | other | 11,014,375 |
| Dec 14, 22 | Primavera Capital Acquisition LLC | sell | 6,014,375 |
| Dec 14, 22 | Primavera Capital Acquisition LLC | other | 11,014,375 |
| Dec 14, 22 | Primavera Capital Acquisition LLC | sell | 10,280,000 |
| Dec 14, 22 | Zhang Chenling | other | 215,625 |
| Dec 14, 22 | Zhang Chenling | sell | 215,625 |
| Dec 14, 22 | Zhang Chenling | other | 215,625 |
| Dec 14, 22 | Teague Teresa Anne | other | 40,000 |
| Dec 14, 22 | Teague Teresa Anne | other | 40,000 |
| Dec 14, 22 | Teague Teresa Anne | sell | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PV coverage
Recent articles, reports, and earnings notes.
No research on PV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PV report →Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
globenewswire.com · Sep 9
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
gurufocus.com · Aug 11
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
gurufocus.com · Aug 10
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
gurufocus.com · Aug 9
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
gurufocus.com · Jul 30
Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera
businesswire.com · Jun 17
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
gurufocus.com · Jun 11
Sigenergy Unveils SigenAgent, the First All-Domain AI Agent for the Renewable Energy Industry
gurufocus.com · May 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.